Journal of Clinical Oncology· 2017Q1
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group
- 510citations
- Q1SCImago
- 2017year
Short summary
In HPV-associated oropharyngeal cancer, induction chemotherapy followed by reduced-dose radiation (54 Gy) and weekly cetuximab achieved 80% 2-year progression-free survival in responders, with significantly fewer swallowing and nutritional issues compared to higher doses.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Otorhinolaryngology
OtorhinolaryngologyMedicine